Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2

Bioconjugate Chemistry

Volumn 19, Issue 12, 2008, Pages 2527-2534

  Sirk, Shannon J ^a,b   Olafsen, Tove ^a   Barat, Bhaswati ^a   Bauer, Karl B ^a   Wu, Anna M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Crump A420   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEXA FLUOR488; ALLOPHYCOCYANIN; ANTIBODY CONJUGATE; CD20 ANTIGEN; CYSTEINE; CYSTEINE DIABODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORESCENT DYE; PHYCOERYTHRIN; THIOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY COMBINING SITE; ANTIBODY ENGINEERING; ANTIGEN BINDING; ARTICLE; CONJUGATION; CONTROLLED STUDY; DISULFIDE BOND; FLOW CYTOMETRY; GEL ELECTROPHORESIS; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ALEXA;

EID: 58149085521     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc800113v     Document Type: Article

References (39)

1. Adams, G. P., and Weiner, L. M. (2005) Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23, 1147-57.
2. Robinson, M. K., Doss, M., Shaller, C., Narayanan, D., Marks, J. D., Adler, L. P., Gonzalez Trotter, D. E., and Adams, G. P. (2005) Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 65, 1471-8.
3. Cai, W., Olafsen, T., Zhang, X., Cao, Q., Gambhir, S. S., Williams, L. E., Wu, A. M., and Chen, X. (2007) PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J. Nucl. Med. 48, 304-10.
4. Olafsen, T., Kenanova, V. E., Sundaresan, G., Anderson, A. L., Crow, D., Yazaki, P. J., Li, L., Press, M. F., Gambhir, S. S., Williams, L. E., Wong, J. Y., Raubitschek, A. A., Shively, J. E., and Wu, A. M. (2005) Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res. 65, 5907-16.
5. Sharkey, R. M., and Goldenberg, D. M. (2006) Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J. Clin. 56, 226-43.
6. Wu, A. M., and Senter, P. D. (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23, 1137-46.
7. Wu, A. M., and Yazaki, P. J. (2000) Designer genes: recombinant antibody fragments for biological imaging. Q. J. Nucl. Med. 44, 268-83.
8. Olafsen, T., Kenanova, V. E., and Wu, A. M. (2006) Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat. Protoc. 1, 2048-60.
9. Albrecht, H., Denardo, G. L., and Denardo, S. J. (2007) Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers. Q. J. Nucl. Med. Mol. Imaging 51, 304-13.
10. Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotny, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., and Crea, R. (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 85, 5879-83.
11. Uchino, J., Takayama, K., Harada, A., Sone, T., Harada, T., Curiel, D. T., Kuroki, M., and Nakanishi, Y. (2008) Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan. Cancer Gene Ther. 15, 94-100.
12. Kortt, A. A., Dolezal, O., Power, B. E., and Hudson, P. J. (2001) Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol. Eng. 18, 95-108.
13. Adams, G. P., Tai, M. S., McCartney, J. E., Marks, J. D., Stafford, W. F., 3rd., Houston, L. L., Huston, J. S., and Weiner, L. M. (2006) Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin. Cancer Res. 12, 1599-605.
14. Behr, T. M., Gotthardt, M., Becker, W., and Behe, M. (2002) Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy. A review of standardized, reliable and safe procedures for clinical grade levels kBq to GBq in the Gottingen/Marburg experience. Nuklearmedizin 41, 71-9.
15. Nikula, T. K., Bocchia, M., Curcio, M. J., Sgouros, G., Ma, Y., Finn, R. D., and Scheinberg, D. A. (1995) Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity. Mol. Immunol. 32, 865-72.
16. McCartney, J. E., Tai, M. S., Hudziak, R. M., Adams, G. P., Weiner, L. M., Jin, D., Stafford, W. F., 3rd., Liu, S., Bookman, M. A., and Laminet, A. A. (1995) Engineering disulfide-linked single-chain Fv dimers [(sFv′)2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv′)2 and anti-c-erbB-2 741F8 (sFv′)2 made by protein folding and bonded through C-terminal cysteinyl peptides. Protein Eng. 8, 301-14.
17. Adams, G. P., McCartney, J. E., Tai, M. S., Oppermann, H., Huston, J. S., Stafford, W. F., 3rd., Bookman, M. A., Fand, I., Houston, L. L., and Weiner, L. M. (1993) Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res. 53, 4026-34.
18. George, A. J., Jamar, F., Tai, M. S., Heelan, B. T., Adams, G. P., McCartney, J. E., Houston, L. L., Weiner, L. M., Oppermann, H., and Peters, A. M. (1995) Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide. Proc. Natl. Acad. Sci. U.S.A. 92, 8358-62.
19. Yang, K., Basu, A., Wang, M., Chintala, R., Hsieh, M. C., Liu, S., Hua, J., Zhang, Z., Zhou, J., Li, M., Phyu, H., Petti, G., Mendez, M., Janjua, H., Peng, P., Longley, C., Borowski, V., Mehlig, M., and Filpula, D. (2003) Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng. 16, 761-70.
20. Weng, K. C., Noble, C. O., Papahadjopoulos-Sternberg, B., Chen, F. F., Drummond, D. C., Kirpotin, D. B., Wang, D., Hom, Y. K., Hann, B., and Park, J. W. (2008) Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett. 8, 2851-7.
21. Messerschmidt, S. K., Kolbe, A., Muller, D., Knoll, M., Pleiss, J., and Kontermann, R. E. (2008) Novel single-chain Fv′ formats for the generation of immunoliposomes by site-directed coupling. Bioconjugate Chem. 19, 362-9.
22. Carmichael, J. A., Power, B. E., Garrett, T. P., Yazaki, P. J., Shively, J. E., Raubischek, A. A., Wu, A. M., and Hudson, P. J. (2003) The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility. J. Mol. Biol. 326, 341-51.
23. Olafsen, T., Cheung, C. W., Yazaki, P. J., Li, L., Sundaresan, G., Gambhir, S. S., Sherman, M. A., Williams, L. E., Shively, J. E., Raubitschek, A. A., and Wu, A. M. (2004) Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng. Des. Sel. 17, 21-7.
24. Bebbington, C., Renner, G., Thomson, S., King, D., Abrams, D., and Yarranton, G. T. (1992) High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selection marker. Biotechnology 10, 169-175.
25. Yazaki, P. J., Shively, L., Clark, C., Cheung, C. W., Le, W., Szpikowska, B., Shively, J. E., Raubitschek, A. A., and Wu, A. M. (2001) Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications. J. Immunol. Methods 253, 195-208.
26. Golay, J., Cittera, E., Di Gaetano, N., Manganini, M., Mosca, M., Nebuloni, M., van Rooijen, N., Vago, L., and Introna, M. (2006) The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 91, 176-83.
27. Pietras, R. J., Arboleda, J., Reese, D. M., Wongvipat, N., Pegram, M. D., Ramos, L., Gorman, C. M., Parker, M. G., Sliwkowski, M. X., and Slamon, D. J. (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10, 2435-46.
28. Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., and Shepard, H. M. (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 89, 4285-9.
29. Barrett, T., Koyama, Y., Hama, Y., Ravizzini, G., Shin, I. S., Jang, B. S., Paik, C. H., Urano, Y., Choyke, P. L., and Kobayashi, H. (2007) In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin. Cancer Res. 13, 6639-48.
30. Koyama, Y., Hama, Y., Urano, Y., Nguyen, D. M., Choyke, P. L., and Kobayashi, H. (2007) Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin. Cancer Res. 13, 2936-45.
31. Natarajan, A., Xiong, C. Y., Albrecht, H., DeNardo, G. L., and DeNardo, S. J. (2005) Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals. Bioconjugate Chem. 16, 113-21.
32. Lee, L. S., Conover, C., Shi, C., Whitlow, M., and Filpula, D. (1999) Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. Bioconjugate Chem. 10, 973-81.
33. Venisnik, K. M., Olafsen, T., Loening, A. M., Iyer, M., Gambhir, S. S., and Wu, A. M. (2006) Bifunctional antibody-Renilla luciferase fusion protein for in vivo optical detection of tumors. Protein Eng. Des. Sel. 19, 453-60.
34. Venisnik, K. M., Olafsen, T., Gambhir, S. S., and Wu, A. M. (2007) Fusion of Gaussia luciferase to an engineered anti-carcinoembryonic antigen (CEA) antibody for in vivo optical imaging. Mol. Imaging Biol. 9, 267-77.
35. Michalet, X., Pinaud, F. F., Bentolila, L. A., Tsay, J. M., Doose, S., Li, J. J., Sundaresan, G., Wu, A. M., Gambhir, S. S., and Weiss, S. (2005) Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307, 538-44.
36. Alexis, F., Rhee, J. W., Richie, J. P., Radovic-Moreno, A. F., Langer, R., and Farokhzad, O. C. (2008) New frontiers in nanotechnology for cancer treatment. Urol. Oncol. 26, 74-85.
37. Kam, N. W., O'Connell, M., Wisdom, J. A., and Dai, H. (2005) Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc. Natl. Acad. Sci. U.S.A. 102, 11600-5.
38. Zheng, G., Patolsky, F., Cui, Y., Wang, W. U., and Lieber, C. M. (2005) Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat. Biotechnol. 23, 1294-301.
39. Gruner, G. (2006) Carbon nanotube transistors for biosensing applications. Anal. Bioanal. Chem. 384, 322-35.